JAMA: No plan to pull elephant-cancer risk paper after PETA protest

JAMAJAMA has decided not to retract an article about cancer risk in elephants after receiving a request to do so from an animal rights group.

People for the Ethical Treatment of Animals (PETA) recently protested the 2015 paper, which found that higher levels of a tumor suppressor gene could explain why elephants have a lower risk of cancer. According to PETA, the paper contained inaccurate information that could be used to justify inhumane treatment of elephants. At the time, the journal told us it considers all calls for retraction.

In an email sent to a representative of PETA over the weekend, Howard Bauchner, Editor in Chief at JAMA and The JAMA Network, wrote: Continue reading JAMA: No plan to pull elephant-cancer risk paper after PETA protest

Two journals retracting papers from University of Malaya featuring widely criticized figures

The image that excited twitter: Figure 6 from the Scientific Reports paper
The image that excited Twitter

One journal has retracted a paper containing images that recently raised suspicions of obvious duplications, and another journal is planning to do the same.

Scientists first leveled accusations against the newly retracted paper in Scientific Reports, along with two others by the same researchers, earlier this month on Twitter. One other journal — PeerJ — has announced that it plans to retract one of the questioned papers, as well. The third paper, in Frontiers in Pharmacology, bears an expression of concern.

It was unusually quick action on the part of the journals, as well as the authors’ host institution, the University of Malaya, which announced last week the authors had manipulated figures in all three papers, along with one other.

Here’s today’s retraction notice from Scientific Reports for “Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties:”

Continue reading Two journals retracting papers from University of Malaya featuring widely criticized figures

Highly cited cancer researcher logs 8th, 9th retractions

Bharat Aggarwal
Bharat Aggarwal

Bharat Aggarwal, a highly cited cancer researcher who retired last year from MD Anderson, has logged two retractions following an investigation into his work, bringing his total to nine.

Aggarwal has threatened to sue us in the past, and told us that MD Anderson has been investigating his work. Earlier this year, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” Now, he’s earned two more retractions in Molecular Pharmacology, both for “inappropriate” or “unacceptable” image manipulation.

Both of the notices are paywalled (tsk, tsk). Here’s one for “Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells:” Continue reading Highly cited cancer researcher logs 8th, 9th retractions

Journal flags paper over allegations it used competitors’ text, plasmids

MGGA journal has issued an expression of concern (EOC) for a paper on a common crop virus after the authors were accused of using competitors’ unpublished text and plasmids.

Investigations by the journal and the involved institutions — the University of the Witwatersrand in South Africa, where the paper’s authors are based, and North Carolina State University (presumably, where the accusing group is from) — were inconclusive, the notice states.

So the editor flagged “Sequences enhancing cassava mosaic disease symptoms occur in the cassava genome and are associated with South African cassava mosaic virus infection” with an EOC:

Continue reading Journal flags paper over allegations it used competitors’ text, plasmids

Seventh retraction appears for cancer researcher who sued PubPeer commenters

sarkar
Fazlul Sarkar

Fazlul Sarkar, who sued PubPeer commenters for criticizing his work, has logged two more retractions, bringing his total to seven.

The two retractions appear in the Journal of Cellular Physiology, and follow five others released last week by another Wiley journal, Journal of Cellular Biochemistry. All notices mention an investigation at Wayne State University, where Sarkar is on the faculty.

Here’s the notice for “Activated K-Ras and INK4a/Arf Deficiency Promote Aggressiveness of Pancreatic Cancer by Induction of EMT Consistent With Cancer Stem Cell Phenotype:” Continue reading Seventh retraction appears for cancer researcher who sued PubPeer commenters

Researcher suing PubPeer commenters earns 5 retractions following investigation

sarkar
Fazlul Sarkar

An investigation at Wayne State University has prompted five retractions for a scientist who is suing PubPeer commenters after they criticized his work on the site.

The investigation into Fazlul Sarkar and his co-authors found that the papers contain images that were “inappropriately manipulated” or “inappropriately re-used and re-labeled.” All five retraction notices are from the Journal of Cellular Biochemistry.

Here’s the retraction notice for “Concurrent inhibition of NF-κB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer:

Continue reading Researcher suing PubPeer commenters earns 5 retractions following investigation

Figures questioned online were manipulated, says Malaysia investigation

The image that excited twitter: Figure 6 from the Scientific Reports paper
The image that set Twitter abuzz: Figure 6 from the Scientific Reports paper, in which every cell in each stage of cell death appeared to be an exact copy.

Many figures in four papers by a research team in Malaysia contain duplication or manipulation, a university committee has found, calling for multiple retractions.

We learned about issues with three of the papers, including one in Scientific Reports, earlier this week when they were the talk of Twitter. As journals issued expressions of concern, and an expert wondered how the papers passed peer review at all, the first author, a researcher at the University of Malaya (UM), denied allegations of duplication.

UM was alerted to allegations of misconduct in the Scientific Reports paper last Saturday, and according to a statement published today:

Continue reading Figures questioned online were manipulated, says Malaysia investigation

Fake email for corresponding author forces neuro journal to retract paper

Cellular and Molecular Neurobiologychair of a neurobiology department in China has requested the retraction of a paper on which he was unwittingly listed as the lead and corresponding author.

How could a corresponding author — you know, the person with whom the journal corresponds about the paper — be added without their consent? It seems that a fraudulent email account was involved in this case. The address listed for Cheng He, a researcher at the Second Military Medical University in Shanghai, didn’t belong to him, said a spokesperson for Springer.

According to the retraction notice for “Identification of the Interaction Between the Human Homologue of the Arabidopsis COP9 Signalosome Subunit 7a and Olig1:”

Continue reading Fake email for corresponding author forces neuro journal to retract paper

Third party company botched student’s doctoral work, says biologist

Cellular Physiology and BiochemistryA PhD student who was supposed to complete part of an experiment passed the job on to a third party company, which in turn provided figures that were plagiarized and fabricated. That’s according to the corresponding author of the paper, which has now been retracted.

Hong Ren, affiliated with Xi’an Jiao Tong University in China, told us that he decided to delay the student’s graduation after he discovered that the student had passed off the work.

It’s not at all obvious that a third party was involved from the brief retraction notice for “EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation:”

Continue reading Third party company botched student’s doctoral work, says biologist

JAMA: No plan to retract article on fetal pain, despite outcry from anti-abortion activists

JAMAJAMA has announced it does not intend to retract a 2005 review article about fetal pain, despite requests from anti-abortion activists who claim it has been misused in debates about the procedure.

Earlier this month, JAMA told one anti-abortion critic that it would take a look at the paper, which suggested that fetuses can’t feel pain before the third trimester. Critics have argued that newer findings have shown pain sensation appears earlier in gestation, yet the 2005 data continue to be cited in the discussion around abortion. What’s more, critics have lamented that some of the authors failed to mention their ties to the abortion industry.

But in a letter sent yesterday to James Agresti, Howard Bauchner, Editor in Chief at JAMA and The JAMA Network, writes: Continue reading JAMA: No plan to retract article on fetal pain, despite outcry from anti-abortion activists